Assessment of average, population and individual bioequivalence in two- and four-period crossover studiesWIJNAND, Herman P.Computer methods and programs in biomedicine. 2003, Vol 70, Num 1, pp 21-35, issn 0169-2607, 15 p.Article

Limits for the scaled average bioequivalence of highly variable drugs and drug productsTOTHFALUSI, Laszlo; ENDRENYI, Laszlo.Pharmaceutical research. 2003, Vol 20, Num 3, pp 382-389, issn 0724-8741, 8 p.Article

Comparative bioavailability of two immediate-release tablets of lisinopril/hydrochlorothiazide in healthy volunteersGASCON, A. R; CUADRADO, A; SOLINIS, M. A et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 7, pp 309-315, issn 0946-1965, 7 p.Article

Comparative bioequivalence study of two isotretinoin soft gel capsule formulations in healthy male volunteersGEORGARAKIS, M; ZOUGROU, F; TZAVARA, S et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 7, pp 316-322, issn 0946-1965, 7 p.Article

Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off propertiesKARALIS, Vangelis; MACHERAS, Panos; SYMILLIDES, Mira et al.European journal of pharmaceutical sciences. 2005, Vol 26, Num 1, pp 54-61, issn 0928-0987, 8 p.Article

Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteersNIOPAS, I; DAFTSIOS, A. C; NIKOLAIDIS, N et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 5, pp 226-230, issn 0946-1965, 5 p.Article

Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalenceDHARIWAL, Kuldeep; JACKSON, Andre.Biopharmaceutics & drug disposition. 2003, Vol 24, Num 5, pp 219-228, issn 0142-2782, 10 p.Article

Critical considerations into the new EMA guideline on bioequivalenceMARZO, Antonio; FONTANA, Elena.Arzneimittel-Forschung. 2011, Vol 61, Num 4, pp 207-220, issn 0004-4172, 14 p.Article

Novel scaled bioequivalence limits with leveling-off propertiesKYTARIOLOS, John; KARALIS, Vangelis; MACHERAS, Panos et al.Pharmaceutical research. 2006, Vol 23, Num 11, pp 2657-2664, issn 0724-8741, 8 p.Article

Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast & Zocor) in healthy human volunteersNAJIB, Naji M; IDKAIDEK, Nasir; ADEL, Ayman et al.Biopharmaceutics & drug disposition. 2003, Vol 24, Num 5, pp 183-189, issn 0142-2782, 7 p.Article

Properties of metrics applied for the evaluation of bioequivalenceJIUHONG ZHA; TOTHFALUSI, L; ENDRENYI, L et al.Drug information journal. 1995, Vol 29, Num 3, pp 989-996, issn 0092-8615Conference Paper

Les généripues: L'avis du pharmaeologuePATHA, Atul.Diabète & obésité. 2012, Vol 7, Num 63, pp 318-320, issn 1957-5238, 3 p.Article

Variability and Impact on Design of Bioequivalence StudiesVAN PEER, Achiel.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 146-153, issn 1742-7835, 8 p.Conference Paper

Statistical evaluation of individual bioequivalenceLIU, J.-P.Communications in statistics. Theory and methods. 1998, Vol 27, Num 6, pp 1433-1451, issn 0361-0926Conference Paper

Risk analysis in bioequivalence and biowaiver decisions : Relationships Between In Vitro Dissolution and In Vivo Response: Part IIKUBBINGA, Marlies; LANGGUTH, Peter; BARENDS, Dirk et al.Biopharmaceutics & drug disposition. 2013, Vol 34, Num 5, pp 254-261, issn 0142-2782, 8 p.Article

Bioequivalence Approaches for Highly Variable Drugs and Drug ProductsHAIDAR, Sam H; DAVIT, Barbara; YU, Lawrence X et al.Pharmaceutical research. 2008, Vol 25, Num 1, pp 237-241, issn 0724-8741, 5 p.Article

Including Information on the Therapeutic Window in Bioequivalence AcceptanceJACOBS, Tom; DE RIDDER, Filip; RUSCH, Sarah et al.Pharmaceutical research. 2008, Vol 25, Num 11, pp 2628-2638, issn 0724-8741, 11 p.Article

Considerations for metabolite pharmacokinetic data in bioavailability / bioequivalence assessments : Overview of the recent trendsSRINIVAS, Nuggehally R.Arzneimittel-Forschung. 2009, Vol 59, Num 4, pp 155-165, issn 0004-4172, 11 p.Article

Open questions on bioequivalence: What about the time interval between two consecutive trials? : Time interval between consecutive trials -short communicationMARZO, Antonio.Arzneimittel-Forschung. 2007, Vol 57, Num 7, pp 505-506, issn 0004-4172, 2 p.Article

Using Partial Area for Evaluation of Bioavailability and BioequivalenceCHEN, Mei-Ling; DAVIT, Barbara; LIONBERGER, Robert et al.Pharmaceutical research. 2011, Vol 28, Num 8, pp 1939-1947, issn 0724-8741, 9 p.Article

Clarithromycin suspension: Bioequivalence studies on two different strengthsKOYTCHEV, Rossen; OZALP, Yildiz; ERENMEMISOGLU, Aydin et al.Arzneimittel-Forschung. 2004, Vol 54, Num 9A, pp 594-599, issn 0004-4172, 6 p.Article

LES GÉNÉRIQUES: L'avis du pharmacologuePATHAK, Atul.Cardiologie cardinale. 2012, Vol 6, Num 51, pp 199-201, issn 1960-1646, 3 p.Article

Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification SystemRAMIREZ, Elena; LAOSA, Olga; GUERRA, Pedro et al.British journal of clinical pharmacology. 2010, Vol 70, Num 5, pp 694-702, issn 0306-5251, 9 p.Article

Biosimilars in rheumatology: pharmacological and pharmacoeconomic issuesLAPADULA, G; FERRACCIOLI, G. F.Clinical and experimental rheumatology (Testo stampato). 2012, Vol 30, Num 4, issn 0392-856X, S102-S106, SUP73Article

Application of Williams' design for bioequivalence trialsMOHANDOSS, E; SHEIN-CHUNG CHOW; KI, F. Y. C et al.Drug information journal. 1995, Vol 29, Num 3, pp 1029-1038, issn 0092-8615Conference Paper